Deep learning predicts onset acceleration of 38 age-associated diseases from blood and body composition biomarkers in the UK Biobank

Mica Xu Ji[1*], Marjola Thanaj[1], Léna Nehale-Ezzine[2], Brandon Whitcher[1], E. Louise Thomas[1], Jimmy D. Bell[1]

[1*]Research Centre for Optimal Health, School of Life Sciences, University of Westminster, London, UK.
[2]Mila – Quebec AI Institute, Montreal, Canada.

*Corresponding author. E-mail: m.ji1@westminster.ac.uk

Abstract

A major challenge in multimorbid aging is understanding how diseases co-occur and identifying high-risk groups for accelerated disease development, but to date associations in the relative onset acceleration of disease diagnoses have not been used to characterise disease patterns. This study presents the development and evaluation of a neural network Cox model for predicting onset acceleration risk for age-associated conditions, using demographic, anthropomorphic, imaging and blood biomarker traits from 60,396 individuals and 218,530 outcome events from the UK Biobank. Risk prediction was evaluated with Harrell's concordance index (C-index). The model performed well on internal (C-index $\mathbf{0.6830 \pm 0.0902}$, $\boldsymbol{n = 8,931}$) and external (C-index $\mathbf{0.6461 \pm 0.1264}$, $\boldsymbol{n = 855}$) test sets, attaining C-index $\boldsymbol{\geq}$ $\mathbf{0.6}$ on 38 out of 47 ($\mathbf{80.9\%}$) conditions. Inclusion of body composition and blood biomarker input traits were independently important for predictive performance. Kaplan-Meier curves for predicted risk quartiles (log-rank $\boldsymbol{p \leq 1.16E - 16}$) indicated robust stratification of individuals into high and low risk groups. Analysis of risk quartiles revealed cardiometabolic, vascular-neuropsychiatric, and digestive-neuropsychiatric disease clusters with strong statistically significant inter-correlated onset acceleration ($\boldsymbol{r \geq 0.6}$, $\boldsymbol{p \leq 3.46E - 5}$), while 13 and 19 conditions were strongly associated with onset acceleration of all cause mortality and all cause morbidity respectively.

In prognostic survival analysis, the proportional hazards assumption was met (Schoenfeld residual $p > 0.05$) in 435 out of 435 or 100% (1238 out of 1334 or 92.8%) of cases across outcomes, $aHR = 6.11 \pm 9.00$ ($aHR = 3.67 \pm 5.78$) with (without) Bonferroni correction. The neural architecture of OnsetNet was interpreted with saliency analysis and several significant body composition and blood biomarkers were identified. The results demonstrate that neural network survival models are able to estimate prognostically informative onset acceleration risk, which could be used to improve understanding of synchronicity in the onset of age-associated diseases and reprioritize patients based on disease-specific risk.

Keywords: multimorbidity, deep learning, healthy aging, UK Biobank

1 Introduction

As we age, the probability of developing more than one condition greatly increases [1]. Multimorbidity, which can be defined as co-occurrence of more than one condition in the same individual, is thus an important problem in aging societies [2, 3], being associated with lower quality of life [4], higher mortality risk [5], and greater usage of healthcare resources than healthy people or those with just one chronic condition [6, 7]. There is a high and increasing prevalence of multimorbidity in the general population, with elderly and socioeconomically deprived groups particularly at risk [1, 8–10]. Chowdhury et al. [11] determined that the global prevalence of multimorbidity was 37.2%, rising to 51.0% in people over 60 years old, while Nunes et al. [12] found that mortality risk of individuals with multimorbidity was 1.73 times greater than those without multimorbidity. Despite these concerns, healthcare delivery systems and quality evaluation remain focused on the treatment of single diseases [13, 14]. An important part of generating an evidence base for improvements in clinical practice is ascertaining patterns of disease and inter-disease associations beyond chance [15].

While epidemiological studies of multimorbidity vary widely in sample size, age settings and statistical methodology, there is a growing consensus that age-associated chronic diseases do not co-occur randomly but in associated fashion,

including conditions across the physical and mental health divide [1, 16]. A 2014 meta-review of 14 studies [15] identified cardiometabolic, neuropsychiatric-gastrointestinal, and musculoskeletal-vascular-neuropsychiatric-gastrointestinal co-occurrence clusters, while more recently [17] identified cardiometabolic, neuropsychiatric, and allergic disease co-occurrence clusters as being commonly reported among 41 studies. The majority of reviewed studies used agglomeration methods such as agglomerative hierarchical clustering and explanatory factor analysis to link diseases on the basis of co-occurrence in individuals, and were not restricted to age-associated conditions. While co-occurrence is important for characterising disease associations, another significant factor is age of disease onset [1]. For example, whether an individual develops cardiovascular disease or hearing loss may be less informative for their health status than age of onset, given that prevalence is estimated at 79-86% and 80.6% in those older than 80 and 85 respectively in the United States [18, 19]. The timing of disease onset has been shown to be informative for risk of secondary diagnoses; early onset cancer is associated with increased risk of cardiovascular disease and secondary cancers compared to later onset cancer [20, 21]. Accelerated biological age estimated using DNA methylation or phenotypic aging clocks has been associated with increased risk of mortality and adverse health outcomes compared to less accelerated biological age [22, 23]. A recent study on chronic diseases [24] found that certain lifestyle factors affected only age of onset and not odds of diagnosis for 10 cardiometabolic, autoimmune and respiratory conditions. Taken together, this suggests that the temporal dimension of multimorbidity may be important for characterising disease patterns.

The present study aims to determine (1) the extent to which onset acceleration risk of age-associated diseases can be accurately predicted from individual traits, and (2) how strongly early onset risk of one disease is associated with early onset risk of another disease beyond chance. To this end, Cox models were trained and evaluated for prediction of individual risk for early onset of diverse age-associated diseases. Using

data from $60,396$ individuals in the UK Biobank imaging cohort [25], we trained a single multimodal neural network, OnsetNet, to predict time-to-event log-risk of the first diagnosis of 47 conditions with birth as temporal baseline, including two composite conditions of all-cause mortality and all-cause morbidity.

First, we evaluated performance of neural network models across disease conditions using C-index measured on internal center and external center held-out test sets, where model hyperparameters were selected by fivefold cross-validation and internal test and C-index ≥ 0.6 was considered acceptable prediction [26]. We compared performance of neural network models on eight different combinations of five input trait groups (demographic, anthropomorphic, summary body composition, spatial body composition, and blood biomarkers) totalling 43 input variables. We assessed performance differences between neural network and linear architectures to evaluate the benefit of using a neural network, which is state-of-the-art and may be a more appropriate choice where it is too simplistic to assume linearity of the log-risk function [27]. OnsetNet score quartiles were computed to illustrate within-disease heterogeneity across onset acceleration risk quartiles. Between-disease risk relationships were analysed by computing all-to-all correlations in OnsetNet risk quartiles between diseases, and clusters containing disease conditions with high inter-correlated onset acceleration risk were identified with agglomerative hierarchical clustering. We trained standard prognostic linear adjusted Cox models (baseline as measurement time, pre-existing diagnoses excluded) with OnsetNet score as an input trait, yielding adjusted hazard ratios across disease pairs. The proportional hazards assumption was tested by examination of Schoenfeld residuals. Finally, the model was analysed with gradient-based saliency to infer relative importance of individual biomarkers and to assess for biological validity of learned associations between biomarkers and disease risk.

OnsetNet's output is interpretable as a metric of accelerated biological aging, given that accelerated biological age can be characterized as event acceleration risk of

age-associated disease from birth [28]. While the present study is purely associative, OnsetNet's ability to stratify individuals into high and low risk groups may be useful for clinical settings, where important problems include early identification of high-risk individuals in order to effectively reduce disease burden on the general population [29] and characterising within-disease heterogeneity due to diversity in pathology [30, 31].

2 Methods

2.1 Study participants

This study was a secondary analysis of longitudinal data from the UK Biobank resource [32] under application number 44584. Data was obtained from the UK Biobank imaging cohort [33] for 60,396 individuals who were initially assessed between April 2007 and October 2010 and had outcomes recorded up to November 30th 2022 (follow-up 13.9 ± 0.819 years, min 12.2 years, max 15.6 years). Eligible individuals had full records of all covariates (29,873 male, 30,523 female, age at imaging 66.2 ± 8.01 years). Where multiple measurements were made, the latest measurement for each individual was taken. Data was split into a training and validation dataset (train-val) containing individuals assessed at Cheadle, Reading, Newcastle and unspecified centers (24,984 male, 25,626 female, age at imaging 66.2 ± 8.00 years), an internal test set containing individuals assessed at train-val centers (4,455 male, 4,476 female, age at imaging 66.0 ± 8.10 years), and an external test set contained individuals assessed at the Bristol center (434 male, 421 female, age at imaging 67.9 ± 7.54 years).

2.2 Covariates

Input variables were selected based on risk factors identified in literature review and were separated into 5 groups. Demographic ("demog") contained sex, race, education level, and Townsend deprivation index. Basic body ("bb") contained weight, height, body mass index (BMI), waist circumference, grip strength, systolic blood pressure,

Fig. 1: Architecture of OnsetNet, a neural network Cox model trained to predict onset acceleration as log-risk of first incidence of 47 disease conditions from individual traits, using birth as temporal baseline. Abbreviations: body mass index (BMI), body mass (MASS), muscle (MUSC), visceral adipose tissue (VAT), glycated haemoglobin (HbA1c), apolipoprotein B (ApoB), insulin-like growth factor 1 (IGF-1), c-reactive protein (CRP), low-density lipoprotein cholesterol (LDL-C).

alcohol consumption, and smoking history. Basic body composition computed from neck-to-knee magnetic resonance imaging scans ("bbc") contained total mass (MASS), total subcutaneous adipose tissue volume (SAT), total muscle volume (MUSC), total visceral adipose tissue volume (VAT), and total thigh intramuscular and intermuscular adipose tissue mass (TMAT). Multidimensional spatial body composition ("sbc") contained MASS, SAT, MUSC, VAT, and TMAT measured along 370 slices across the vertical height dimension. Blood-based biomarkers ("blood") contained low-density lipoprotein cholesterol (LDL-C), triglycerides, apolipoprotein A (ApoA), apolipoprotein B (ApoB), cholesterol, high-density lipoprotein cholesterol (HDL-C), glucose, glycated haemoglobin (HbA1c), insulin-like growth factor 1 (IGF-1), urate, urea, total

protein, alanine aminotransferase (ALT), albumin (ALB), alkaline phosphatase (ALP), aspartate aminotransferase (AST), c-reactive protein (CRP), calcium (Ca), creatinine, cystatin C, gamma glutamyltransferase (GGT), phosphate, sex hormone binding globulin (SHBG), total bilirubin, and vitamin D.

For non-demographic variables, age at trait measurement was provided as an additional input variable with the measurement (Figure 1). Continuous input variables were scaled to zero mean and unit standard deviation using statistics from the train-val dataset, and discrete input variables were represented with one-hot encodings. Body composition variables were computed by automated segmentation of MRI instances by a previously published deep learning system that was used to produce publicly available UK Biobank body composition variables [34–37]. In brief, UNet [38] based deep learning models were trained to segment body composition tissues from UKBiobank neck-to-knee Dixon acquisitions using manual annotations. The UKBiobank protocol utilized the Siemens Aera 1.5T scanner (Syngo MR D13) and is detailed in [33].

Outcomes for 47 age-related conditions were chosen using literature on aging and multimorbidity [39, 40]. We obtained date of first occurrence for 45 non-composite disease categories defined by ICD10 codes (Appendix A.4) from the UK Biobank first occurrence register, which incorporates primary care, hospital inpatient, death register and self-reported records. Date of death was taken from the death register and date for all-cause morbidity was taken as first occurrence date for any of the 45 non-composite disease categories.

2.3 Deep learning estimation of onset acceleration risk

Neural network models trained to predict onset acceleration risk consisted of separate encoders per trait group each producing a feature vector of fixed length $k \in \{128, 256, 512\}$, followed by feature concatenation and a shared predictor head

with one scalar output for each disease condition (Figure 1). Neural networks had an average of $2.31E6 \pm 1.00E6$ parameters (min 8.54E5, max 4.92E6, Appendix B).

Fivefold cross-validation was used to train models on the train-val dataset by optimizing objective $l(\theta)$, the Cox proportional hazard (Cox PH) partial log-likelihood objective function with weight decay regularization [41] over 47 disease conditions $d \in \mathcal{D}$:

$$g^d(\theta) = -\frac{1}{N_{E^d=1}} \sum_{i:E_i^d=1} \left(h_\theta^d(x_i) - \log \sum_{j \in \mathcal{R}^d(T_i^d)} e^{h_\theta^d(x_j)} \right),$$

$$l(\theta) = \frac{1}{|\mathcal{D}|} \sum_{d \in \mathcal{D}} g^d(\theta) + \lambda \|\theta\|_2^2,$$

where θ are model parameters, λ is the weight decay coefficient, x_i are input traits for individual i, log-risk $h_\theta^d(x_i)$ is the scalar output of the model for disease condition d and individual i, E^d is the censoring vector for d where $E_i^d = 1$ (uncensored) if individual with index i received a diagnosed for d and $E_i^d = 0$ (censored) otherwise. $N_{E^d=1}$ is the number of uncensored individuals for d. Birth was used as temporal baseline and time to event was measured in years (Figure 2). T_i^d is age at first diagnosis for individual i with a diagnosis of d and otherwise age at censor date (November 30th 2022), risk set $\mathcal{R}^d(t) = \{i : T_i^d \geq t\}$ is the set of individuals undiagnosed with d at age t.

To evaluate performance, test sets were unseen during model selection of neural network Cox models and linear Cox comparison baselines. Hyperparameter values (λ, k, learning rate, dropout rate) for each input trait group combination were chosen by average validation fold C-index. Computation of C-index

Fig. 2: Cox models commonly predict risk of event earliness from measurement baseline while OnsetNet models event earliness from birth.

was batched with batch size of 2048 for tractability [27]. Neural networks were implemented in Python with GPU-accelerated PyTorch 2.4.1 and linear models in R 4.1.2. The code will be made available upon publication.

2.4 Statistical analysis

To investigate onset acceleration risk correlation between conditions, Pearson's r was computed between OnsetNet score quartiles $q \in [1, 4]$ for all pairs of conditions with internal test C-index performance ≥ 0.6. Correlation of $r \geq 0.6$ was considered strong and $p \leq 3.46E - 5$ was considered significant. Using the all-pairs correlation matrix, a clustering dendrogram was computed using unweighted pair group method with arithmetic mean (UPGMA) hierarchical agglomerative clustering for the linkage function (SciPy *cluster.hierarchy.linkage*) with cosine distance between correlation vectors as the clustering metric. Statin users (12,157 out of 60,396 in the study cohort reporting statin medication usage in verbal interview) were removed, and sensitivity analyses were conducted for removal of Bonferroni correction and inclusion of statin users.

To evaluate the prognostic ability of onset acceleration scores, a prognostic Cox model was trained for each pair of disease conditions (A, B), with OnsetNet risk quartile for condition A as input and individual log-risk of time-to-event for first occurrence of condition B as output. Baseline time was taken as imaging assessment time, corresponding to the latest date across input trait measurements, outcome events were within 10 years of baseline, individuals with pre-existing diagnoses were excluded, and time-to-event was measured in months. Demographic traits were included as input covariates for primary adjustment of hazard ratios, and secondary adjustment for both demographic and basic body traits was also performed to test for sensitivity. 6 outcome conditions with greater than 75% allocation to either sex (female: gynecological problems, thyroid diseases, osteoporosis; male: prostatic hyperplasia, hyperuricemia/gout, sexual dysfunction) were trained for the dominant sex only. Outcome events

for 3 conditions with fewer than 50 uncensored individuals after removal of pre-imaging diagnoses were removed (hemorrhoids, Parkinson's disease, and somatoform disorders).

Two-tailed tests were used to compute p-values and Bonferroni corrections were made at $p = 0.05$ level. The study adhered to the EQUATOR TRIPOD+ AI [42] guidelines for transparent reporting of an AI multivariable prediction model and STROBE [43] guidelines for reports of observational studies. Completed checklists are given in Appendix D.

3 Results

3.1 Predictive performance

A summary of participant characteristics for training and test datasets is given in Table 1. Eight different combinations of trait group inputs were evaluated for the neural network OnsetNet architecture and compared to a linear architecture (Table 2). High-dimensional spatial body composition was utilized for neural network models but not linear models due to correlation in body composition along the height dimension. The OnsetNet full traits model (demog+bb+bbc+sbc+blood) attained the highest internal test C-index ($0.6830 \pm 9.02E - 2$), highest combined internal and external test C-index ($0.6647 \pm 1.11E - 1$), and highest validation C-index ($0.6856 \pm 9.08E - 1$) on average over conditions and cross-validation data folds. On the external test set, OnsetNet demog+bb+bbc+blood ($0.6472 \pm 1.23E - 1$) performed best on C-index, followed by OnsetNet full traits ($0.6461 \pm 1.26E - 1$). While performance differences between top OnsetNet models and the linear model were not statistically significant by estimated p-value, larger differences between models were statistically significant (Table 2, Table C10), and the linear model was consistently outperformed by neural networks on all metrics. Within specific conditions, diabetes mellitus non-T1 ($0.940 \pm$

Table 1: Characteristics of UK Biobank participants used for the present study. p-values were computed with two-tailed t-test for continuous variables and χ^2-test for categorical variables.

Trait	Train-val Value (ref.)	Internal test Value	Internal test p-value	External test Value	External test p-value
n	50,610	8,931	–	855	–
Age at baseline (yrs)	54.89 ±7.57	54.74 ±7.68	9.80E-02	54.29 ±7.53	2.13E-02
Sex			9.18E-01		7.80E-01
Female	50.63	50.12		49.24	
Race			9.99E-01		9.64E-01
White	96.66	96.93		97.31	
Education			1.00E+00		9.99E-01
College or University degree	45.66	45.45		46.20	
Smoking			9.99E-01		4.71E-01
Never	61.57	60.83		58.83	
Alcohol			1.00E+00		9.67E-01
Three or four times a week	27.84	27.16		25.50	
BMI (Kg/m^2)	26.55 ±4.35	26.61 ±4.42	2.20E-01	26.09 ±4.38	2.51E-03
Grip strength (Kg)	30.43 ±10.61	30.68 ±10.65	4.64E-02	30.23 ±10.28	5.76E-01
HbA1c ($mmol/mol$)	35.04 ±5.09	35.07 ±5.16	7.22E-01	34.62 ±4.70	1.55E-02
HDL-C ($mmol/L$)	1.47 ±0.37	1.47 ±0.37	6.20E-01	1.46 ±0.36	3.37E-01
ApoB (g/L)	1.01 ±0.21	1.01 ±0.21	7.74E-01	1.01 ±0.22	9.84E-01
Hypertension (%)	31.03	31.51	9.18E-01	32.98	6.74E-01
Diabetes mellitus non-T1 (%)	5.56	5.78	9.26E-01	4.80	7.37E-01
Depression (%)	11.03	11.29	9.34E-01	11.93	7.73E-01

$3.06E - 3$ for OnsetNet full traits) and severe vision reduction ($0.550 \pm 2.54E - 3$ for OnsetNet full traits) performed best and worst on internal test respectively (Figure 3).

We analysed the importance of adding individual trait groups to model inputs (Table C10). The largest performance gains on internal test C-index from adding traits to model inputs were adding bb to demog ($\Delta 0.0542$, $p = 9.68E - 15$), sbc to demog+bb ($\Delta 0.0295$, $p = 4.81E - 5$), and blood to demog+bb ($\Delta 0.0272$, $p = 4.48E - 4$). On internal and external test sets, utilizing body composition traits increased performance and was approximately twice as important in the absence of blood biomarkers. On internal test set C-index, adding bbc to demog+bb

Table 2: Test set performance across models measured by C-index. C-index values denote average over 47 conditions and 5 cross-valiation folds. *p*-values measure significance of difference with linear demog+bb+bbc+blood and were computed with two-tailed t-test. Bold font denotes top two methods for each metric.

Method	Internal test C-index	External test C-index	All test C-index
Linear			
demog+bb+bbc+blood	$6.782E-01$ $\pm 9.11E-02$	$6.435E-01$ $\pm 1.50E-01$	$6.611E-01$ $\pm 1.25E-01$
OnsetNet			
demog	$5.863E-01$ $\pm 6.96E-02$ $(p\text{=}2.73\text{E-}51)$	$5.683E-01$ $\pm 1.06E-01$ $(p\text{=}8.05\text{E-}14)$	$5.774E-01$ $\pm 9.01E-02$ $(p\text{=}1.84\text{E-}45)$
demog+bb	$6.404E-01$ $\pm 7.66E-02$ $(p\text{=}4.55\text{E-}10)$	$6.187E-01$ $\pm 1.35E-01$ $(p\text{=}1.41\text{E-}02)$	$6.297E-01$ $\pm 1.10E-01$ $(p\text{=}1.16\text{E-}07)$
demog+bb+bbc	$6.649E-01$ $\pm 7.81E-02$ $(p\text{=}2.74\text{E-}02)$	$6.304E-01$ $\pm 1.21E-01$ $(p\text{=}1.93\text{E-}01)$	$6.478E-01$ $\pm 1.03E-01$ $(p\text{=}2.50\text{E-}02)$
demog+bb+sbc	$6.699E-01$ $\pm 7.88E-02$ $(p\text{=}1.69\text{E-}01)$	$6.309E-01$ $\pm 1.23E-01$ $(p\text{=}2.10\text{E-}01)$	$6.506E-01$ $\pm 1.05E-01$ $(p\text{=}7.68\text{E-}02)$
demog+bb+blood	$6.677E-01$ $\pm 8.95E-02$ $(p\text{=}8.25\text{E-}02)$	$6.431E-01$ $\pm 1.34E-01$ $(p\text{=}9.65\text{E-}01)$	$6.555E-01$ $\pm 1.14E-01$ $(p\text{=}3.48\text{E-}01)$
demog+bb+bbc+blood	$6.799E-01$ $\pm 9.06E-02$ $(p\text{=}7.84\text{E-}01)$	$\mathbf{6.472E-01}$ $\mathbf{\pm 1.23E-01}$ $\mathbf{(p\text{=}7.16\text{E-}01)}$	$\mathbf{6.637E-01}$ $\mathbf{\pm 1.09E-01}$ $\mathbf{(p\text{=}6.54\text{E-}01)}$
demog+bb+sbc+blood	$\mathbf{6.820E-01}$ $\mathbf{\pm 9.02E-02}$ $\mathbf{(p\text{=}5.41\text{E-}01)}$	$6.446E-01$ $\pm 1.27E-01$ $(p\text{=}9.17\text{E-}01)$	$6.635E-01$ $\pm 1.11E-01$ $(p\text{=}6.85\text{E-}01)$
demog+bb+bbc+sbc+blood	$\mathbf{6.830E-01}$ $\mathbf{\pm 9.02E-02}$ $\mathbf{(p\text{=}4.37\text{E-}01)}$	$\mathbf{6.461E-01}$ $\mathbf{\pm 1.26E-01}$ $\mathbf{(p\text{=}7.99\text{E-}01)}$	$\mathbf{6.647E-01}$ $\mathbf{\pm 1.11E-01}$ $\mathbf{(p\text{=}5.36\text{E-}01)}$

increased performance by $\Delta 0.0244$ ($p = 6.85E-4$), sbc to demog+bb by $\Delta 0.0295$ ($p = 4.81E-5$), bbc to demog+bb+blood by $\Delta 0.0122$ ($p = 1.42E-1$), and sbc to demog+bb+blood by $\Delta 0.0143$ ($p = 8.59E-2$). For models with blood traits included, small gains were observed on internal test C-index from utilizing increasingly complex body composition inputs (demog+bb+bbc+blood: $0.6799 \pm 9.08E-2$, demog+bb+sbc+blood: $0.6820 \pm 9.04E-2$, demog+bb+bbc+sbc+blood: $0.6830 \pm$

Fig. 3: Internal test set C-index across disease conditions for linear and neural network architectures. Grey error bars illustrate 95% confidence intervals.

$9.04E − 2$), but performance on the external test set was highest for basic body composition (demog+bb+bbc+blood: $0.6472 \pm 1.233E − 1$, demog+bb+sbc+blood: $0.6446 \pm 1.269E − 1$, demog+bb+bbc+sbc+blood: $0.6461 \pm 1.264E − 1$). C-index was lower ($\Delta − 0.0306 \pm 0.0080$) with higher variance on the external test set compared to the internal test set for all input trait combinations.

Following model selection and performance evaluation, the full dataset was utilized for post-hoc analysis. The best performing neural network by both average validation C-index and test C-index was demog+bb+bbc+sbc+blood which provided OnsetNet scores for analysis. Onset acceleration score quartiles were computed by discretizing

Fig. 4: Kaplan-Meier survival curves of age in years (horizontal axis) against survival probability (vertical axis) for OnsetNet risk quartiles. All conditions and at-risk counts are given in Appendix C.

OnsetNet scores using sex and condition specific quartile bins computed on the train-val dataset. Kaplan-Meier estimates for onset acceleration score quartile illustrated within-condition heterogeneity (Figure 4).

3.2 Inter-disease onset acceleration analysis

Pearson's r was computed between OnsetNet score quartiles for each pair of 38 conditions where both conditions had internal test C-index performance ≥ 0.6 (Figure 5, Figure 6). 1420 out of 1444 correlations were significant at $p \leq 3.46E-5$ level (Bonferroni corrected, $p = 5.87E-9 \pm 9.81E-8$) including all strong correlations ($r \geq 0.6$). Disease clusters and strong correlations were reproduced in sensitivity analysis without Bonferroni correction ($p \leq 0.05$) or with inclusion of statin users (Appendix C).

Onset acceleration risk quartile for all cause mortality and all cause morbidity were strongly correlated with each other ($r = 0.78$) and jointly strongly correlated with anxiety ($r = 0.86, 0.82$), dementia ($r = 0.84, 0.82$), depression ($r = 0.80, 0.83$), migraine/chronic headache ($r = 0.77, 0.69$), cardiac valve disorders ($r = 0.75, 0.65$), sexual dysfunction ($r = 0.73, 0.67$), hypotension ($r = 0.69, 0.63$), cardiac arrhythmias ($r = 0.64, 0.63$), and rheumatoid arthritis/chronic polyarthritis ($r = 0.63, 0.79$). Insomnia ($r = 0.81$), chronic gastritis/GERD ($r = 0.78$), intestinal diverticulosis ($r = 0.75$), liver disease ($r = 0.72$), cardiac insufficiency ($r = 0.69$), neuropathies ($r = 0.68$), urinary incontinence ($r = 0.68$), obesity ($r = 0.67$), and urinary tract calculi ($r = 0.63$) were strongly correlated with all cause morbidity but not with all cause mortality. Correlation between onset acceleration risk in obesity and all cause mortality was $r = 0.43$. Conversely, all cause mortality was strongly correlated with Parkinson's disease ($r = 0.72$), anemia ($r = 0.68$), and atherosclerosis/PAOD ($r = 0.62$), which were not strongly correlated with all cause morbidity. The two strongest onset acceleration correlations with Parkinson's disease were dementia ($r = 0.73$) and all cause mortality ($r = 0.72$).

Within non-composite conditions, onset acceleration risk clusters were identified by cosine distance between correlation vectors. A cardiometabolic cluster (corners of Figure 5) was identified where lipid metabolism disorders were associated with chronic ischemic heart disease ($r = 0.79$), hypertension ($r = 0.79$), cerebral ischemia/chronic

Fig. 5: Clusterplot illustrating structure in the onset acceleration risk of age-associated diseases. Onset acceleration risk quartile correlations for conditions with internal test C-index ≥ 0.6 were clustered by hierarchical agglomerative clustering with cosine distance between correlation vectors as the clustering metric. Color denotes risk quartile correlation strength. Statin users were removed and 24 out of 1444 entries with $p > 3.46E - 5$ (Bonferroni corrected) were set to 0 for cosine distance. Row and column colours indicate condition types.

stroke ($r = 0.70$), diabetes mellitus non-T1 ($r = 0.63$), hyperuricemia/gout ($r = 0.61$), and chronic cholecystitis/gallstones ($r = 0.60$) in a cluster that did not include obesity ($r = 0.35$).

Fig. 6: Graph of inter-disease OnsetNet risk quartile correlations for conditions with internal test C-index ≥ 0.6 and correlations with $r \geq 0.3$ and $p \leq 3.46E{-}5$ (Bonferroni corrected). Statin users were removed and r scales with edge width.

Second, chronic gastritis/GERD was associated with a mixed digestive and neuropsychiatric cluster (lower right, Figure 5) containing intestinal diverticulosis ($r = 0.85$), rheumatoid arthritis/chronic polyarthritis ($r = 0.79$), all cause morbidity ($r = 0.78$), urinary tract calculi ($r = 0.77$), insomnia ($r = 0.77$), depression ($r = 0.75$), anxiety ($r = 0.73$), liver disease ($r = 0.73$), neuropathies ($r = 0.71$), chronic cholecystitis/gallstones ($r = 0.71$), urinary incontinence ($r = 0.66$), obesity ($r = 0.63$), dementia ($r = 0.63$), chronic ischemic heart disease ($r = 0.60$), cardiac insufficiency ($r = 0.60$), and thyroid diseases ($r = 0.60$).

Third, a vascular-neuropsychiatric cluster was identified (upper left, Figure 5), where onset acceleration risk in cardiac insufficiency was strongly associated with cardiac arrhythmias ($r = 0.80$), dementia ($r = 0.75$), hypotension ($r = 0.73$), rheumatoid arthritis/chronic polyarthritis ($r = 0.71$), cardiac valve disorders ($r = 0.71$), depression ($r = 0.70$), all cause morbidity ($r = 0.69$), atherosclerosis/PAOD ($r = 0.69$),

insomnia ($r = 0.68$), thyroid diseases ($r = 0.68$), anxiety ($r = 0.68$), urinary incontinence ($r = 0.67$), parkinson's disease ($r = 0.64$), anemia ($r = 0.62$), neuropathies ($r = 0.61$), chronic gastritis/GERD ($r = 0.60$), and bronchitis/COPD ($r = 0.60$).

Notable associations within the vascular-neuropsychiatric cluster included anxiety and depression ($r = 0.9$) which demonstrated the strongest correlation in onset acceleration risk overall, with top shared correlations for all cause mortality ($r = 0.86, 0.80$), all cause morbidity ($r = 0.82, 0.83$), dementia ($r = 0.81, 0.81$), migraine/chronic headache ($r = 0.78, 0.77$), rheumatoid arthritis/chronic polyarthritis ($r = 0.77, 0.79$), hypotension ($r = 0.76, 0.73$), sexual dysfunction ($r = 0.74, 0.71$), anemia ($r = 0.74, 0.67$), chronic gastritis/GERD ($r = 0.73, 0.75$), cardiac valve disorders ($r = 0.71, 0.67$), insomnia ($r = 0.71, 0.79$), intestinal diverticulosis ($r = 0.69, 0.73$), liver disease ($r = 0.69, 0.69$), cardiac insufficiency ($r = 0.68, 0.70$), urinary incontinence ($r = 0.67, 0.69$), cardiac arrhythmias ($r = 0.64, 0.63$), neuropathies ($r = 0.63, 0.66$), parkinson's disease ($r = 0.62, 0.62$), gynecological problems ($r = 0.61, 0.60$), and urinary tract calculi ($r = 0.60, 0.62$). The strongest association with anemia was hypotension and vice versa ($r = 0.84$).

3.3 Prognostic survival analysis

Adjusted hazard ratios (aHR) for OnsetNet Q4 (Q1 as reference) for 47 input conditions and 44 outcome event conditions were rendered (Figure 7). 1334 out of 2068 (64.5%) hazard ratios were significant at $p = 0.05$ level after primary adjustment without Bonferroni correction, of which Schoenfeld residuals were insignificant ($p > 0.05$) for 1238 or 92.8% ($aHR = 3.67 \pm 5.78$), and 1037 or 77.7% remained statistically significant after secondary adjustment. 435 out of 2068 (21.0%) hazard ratios were significant at $p = 9.05E - 7$ level (Bonferroni corrected $p = 0.05$) after primary adjustment ($aHR = 6.11 \pm 9.00$), where all Schoenfeld residuals were insignificant ($p > 0.05$), and 184 (42.3%) remained statistically significant after secondary adjustment. With

Fig. 7: Adjusted log hazard ratios for OnsetNet risk Q4 (Q1 as reference) given primary adjustment with demographic variables. Color red (blue) indicates positive (negative) log hazard ratios and color intensity scales with log hazard ratio magnitude. Gray cells denote log hazard ratios that were statistically insignificant following primary adjustment ($p > 9.05E-7$, Bonferroni corrected) or where Schoenfeld residual $p \leq 0.05$. Entries that remained statistically significant after secondary adjustment with basic body traits are underlined to denote robustness to change in adjustment.

Bonferroni correction, 25 out of 44 (56.8%) input conditions yielded statistically significant Q4 hazard ratios for the same outcome condition ($aHR = 11.09 \pm 17.8$), and 27 statistically significant Q4 hazard ratios were observed for all cause mortality ($aHR = 6.26 \pm 9.33$) of which 23 were strong with at least threefold increase in mortality risk compared to Q1 ($aHR \geq 3$, $aHR = 6.85 \pm 9.98$). Using binarized OnsetNet score instead of quartiles (above median vs. below median, Appendix C) yielded 23 statistically significant adjusted hazard ratios for all cause mortality with Bonferroni correction ($aHR = 2.24 \pm 0.408$) of which only 2 were strong (all cause mortality

and dementia, $aHR = 3.39 \pm 0.222$), suggesting that onset acceleration risk Q4 was disproportionately associated with mortality hazard compared to lower quartiles.

3.4 Biomarker saliency

To investigate the relationship learned by the neural network between input traits and onset acceleration risk of conditions, we computed sex-specific normalized absolute partial derivative of network input variables with respect to each output [44, 45]. Univariate traits (Figure 8) and multivariate spatial body composition (Figure 9) were normalized separately.

Known relationships inferred by saliency without a-priori knowledge include creatinine and cystatin C for renal insufficiency, HbA1c for diabetes mellitus non-T1, urate for hyperuricemia/gout, GGT for liver disease, total MASS for obesity, systolic blood pressure for hypertension and hypotension. Notably, BMI and total MASS were not in the top 5 traits for onset acceleration risk of diabetes mellitus non-T1, which was dominated by HbA1c. The 10 most important individual traits on average over conditions for the full traits OnsetNet model were total MASS, total SAT, total MUSC, total VAT, grip strength, GGT, HbA1c, HDL-C for both males and females, ApoB and cholesterol for males, and AST and total TMAT for females. Additional traits in the top 10 for the full univariate traits model included smoking, total TMAT, and urate for males, and alcohol, smoking and urate for females (Appendix C). The most salient spatial body composition regions were VAT and MASS located at the abdomen for males, and muscle and MASS around the abdomen for females on average over conditions. Less overt relationships inferred for both sexes included HBA1c, HDL-C and urate for anemia; GGT, ApoB, AST and body composition for dementia; urate for osteoporosis; total MASS, HBA1c and grip strength for insomnia. Total MASS was highly salient for chronic low back pain, and total TMAT was highly salient for cardiac

Fig. 8: Saliency map for univariate traits for (a) male and (b) female participants. Top 5 salient traits per condition are labelled. Average saliency across conditions given in the bottom row.

Fig. 9: Spatial body composition saliency maps averaged over 47 conditions for (a) male and (b) female participants. Condition-specific maps are given in Appendix C.5.

conditions (arrhythmias, insufficiency, valve disorders). For both sexes, body composition traits were more salient than blood biomarkers for predicting onset acceleration of dementia and Parkinson's disease; the top five univariate biomarkers for Parkinson's disease were basic body composition traits. ALT was salient for liver disease but not in the top 5 traits, which featured AST and GGT.

4 Discussion

For the methodological contribution of the study, we validated that onset acceleration risk of diverse age-associated diseases can be modelled using neural network and linear Cox architectures, with neural networks outperforming linear models on in-distribution and out-of-distribution test data. While there was high variability in predictive performance across conditions, the final model selected by cross-validation utilized all input traits and attained internal test C-index ≥ 0.6 on 38 out of 47 conditions (80.9%). Model applicability was not limited by temporal differences in trait measurement times (11.3 ± 3.03 years between blood samples and imaging scans for individuals in this study) since the relevant period is lifespan instead of post-measurement time. Inclusion of body composition was found to be important for predictive performance across disease conditions, with performance gain from adding body composition metrics to

basic demographic and anthropomorphic traits being comparable to the performance gain from adding blood biomarkers.

In post-hoc analysis, a number of connections between diseases with existing support in the literature were inferred without a-priori knowledge, such as associations in onset correlation risk between Parkinson's disease, dementia and all cause mortality, cardiovascular and cerebrovascular conditions [16, 39, 46]. Strong correlations in onset acceleration risk were inferred for cardiometabolic, digestive-neuropsychiatric, and vascular-neuropsychiatric condition groups, partially corroborating a previous review of cross-sectional multimorbidity studies across different populations which identified cardiometabolic, neuropsychiatric-gastrointestinal, and musculoskeletal-vascular-neuropsychiatric-gastrointestinal co-occurrence clusters [15] despite the use of different methodology that associated diseases by co-occurrence. Automated inference of associations between biomarkers and disease identified pre-supported associations in a precise manner, including biomarkers for renal insufficiency, diabetes and liver disease, adding to previous work that used partial derivative based saliency to identify biologically salient factors for disease [45]. Saliency analysis validated the importance of grip strength and body composition traits [47].

This study is subject to several limitations. Firstly, existing work showed that the UK Biobank cohort contains a healthy participant bias and is predominantly composed of individuals from White ethnic backgrounds [48]. Although models adjusted for sociodemographic factors, conclusions drawn may not hold for more representative or ethnically diverse populations. All conditions except all cause mortality were reliant on the timing and definition of diagnoses, which depends on factors such as access to healthcare services and diagnostic criteria. Underestimation of disease prevalence in the UK Biobank is known to occur secondary to underdiagnosis [49, 50]. While Cox models are the dominant survival analysis approach in medical research and clinical trials [51, 52] and have been used for time-to-death analysis of aging clocks [22], it is an

approximate model of survival as the proportional hazards assumption generally does not hold perfectly. In this exploratory analysis, results from evaluation against ground truth event times (Table 2, Figures 3, 4, 7) indicated that the Cox PH objective was capable of training models to predict onset acceleration risk, but alternative models may also be applied in future work. Additionally, models were assessed on held-out in-distribution and out-of-distribution test sets but are yet to be evaluated on an entirely independent cohort, and direct clinical utility and explicit causal relationships were not assessed. Prospective and intervention based studies are required to show clinical utility and support the validity of associations inferred in this study.

In summary, we introduced and evaluated the use of Cox models for modelling onset acceleration risk in the context of multimorbid aging, and performed analysis on inter-disease relationships, within-disease heterogeneity across individuals, and biomarker saliency for onset acceleration risk prediction. This work opens up novel approaches for the analysis of age-related diseases and associated biomarker predictor traits, with potential clinical applicability to early identification of high-risk groups in the population.

Declarations

Acknowledgements

The authors would like to thank the UK Biobank Reading team, Madeleine Cule, Ramprakash Srinivasan, Adam Kosiorek, and Martin Tobin for their support.

Sources of Funding

Institutional funding for the study was provided by Calico Life Sciences LLC.

Disclosures

The authors report no conflicts of interest.

Author statement

M. X. Ji conducted literature search, study design, data curation and verification, model training and data analysis, results interpretation, figures, writing first draft, and writing review and edits. M. Thanaj conducted literature search, study design, data curation and verification, results interpretation, and writing review and edits. L. Néhale-Ezzine, B. Whitcher, E. L. Thomas, and J. D. Bell conducted results interpretation, and writing review and edits.

Data access statement

Participant data from the UK Biobank cohort was obtained through UK Biobank Access Application number 44584. The UK Biobank has approval from the North West Multi-center Research Ethics Committee (REC reference: 11/NW/0382). All methods were performed in accordance with the relevant guidelines and regulations, and informed consent was obtained from all participants. Researchers may apply to use the UK Biobank data resource by submitting a health-related research proposal that is in the public interest. More information may be found on the UK Biobank researchers and resource catalogue pages (www.ukbiobank.ac.uk). No participant or public involvement occurred during the design, conduct, reporting, interpretation, or dissemination of this study.

References

[1] Barnett, K., Mercer, S.W., Norbury, M., Watt, G., Wyke, S., Guthrie, B.: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet **380**(9836), 37–43 (2012)

[2] Pearson-Stuttard, J., Ezzati, M., Gregg, E.W.: Multimorbidity—a defining challenge for health systems. The Lancet Public Health **4**(12), 599–600 (2019)

[3] Valderas, J.M., Starfield, B., Sibbald, B., Salisbury, C., Roland, M.: Defining comorbidity: implications for understanding health and health services. The Annals of Family Medicine **7**(4), 357–363 (2009)

[4] Williams, J.S., Egede, L.E.: The association between multimorbidity and quality of life, health status and functional disability. The American journal of the medical sciences **352**(1), 45–52 (2016)

[5] Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A.S., Bansal, N., O'Keeffe, L.M., Gao, P., Wood, A.M., Burgess, S., *et al.*: Association of cardiometabolic multimorbidity with mortality. Jama **314**(1), 52–60 (2015)

[6] Frølich, A., Ghith, N., Schiøtz, M., Jacobsen, R., Stockmarr, A.: Multimorbidity, healthcare utilization and socioeconomic status: a register-based study in denmark. PloS one **14**(8), 0214183 (2019)

[7] Struijs, J.N., Baan, C.A., Schellevis, F.G., Westert, G.P., Van Den Bos, G.A.: Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. BMC health services research **6**, 1–9 (2006)

[8] Uijen, A.A., Lisdonk, E.H.: Multimorbidity in primary care: prevalence and trend over the last 20 years. The European journal of general practice **14**(sup1), 28–32 (2008)

[9] Kone, A.P., Mondor, L., Maxwell, C., Kabir, U.S., Rosella, L.C., Wodchis, W.P.: Rising burden of multimorbidity and related socio-demographic factors: a repeated cross-sectional study of ontarians. Canadian Journal of Public Health **112**, 737–747 (2021)

[10] Moreno-Juste, A., Gimeno-Miguel, A., Poblador-Plou, B., Calderón-Larrañaga,

A., Del Pozo, M.C., Forjaz, M.J., Prados-Torres, A., Gimeno-Feliú, L.A.: Multimorbidity, social determinants and intersectionality in chronic patients. results from the epichron cohort. Journal of Global Health **13** (2023)

[11] Chowdhury, S.R., Das, D.C., Sunna, T.C., Beyene, J., Hossain, A.: Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis. EClinicalMedicine **57** (2023)

[12] Nunes, B.P., Flores, T.R., Mielke, G.I., Thume, E., Facchini, L.A.: Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Archives of gerontology and geriatrics **67**, 130–138 (2016)

[13] Tinetti, M.E., Fried, T.R., Boyd, C.M.: Designing health care for the most common chronic condition—multimorbidity. Jama **307**(23), 2493–2494 (2012)

[14] Ong, K.Y., Lee, P.S.S., Lee, E.S.: Patient-centred and not disease-focused: a review of guidelines and multimorbidity. Singapore medical journal **61**(11), 584 (2020)

[15] Prados-Torres, A., Calderón-Larrañaga, A., Hancco-Saavedra, J., Poblador-Plou, B., Akker, M.: Multimorbidity patterns: a systematic review. Journal of clinical epidemiology **67**(3), 254–266 (2014)

[16] Whitty, C.J., Watt, F.M.: Map clusters of diseases to tackle multimorbidity. Nature **579**(7800), 494–496 (2020)

[17] Ng, S.K., Tawiah, R., Sawyer, M., Scuffham, P.: Patterns of multimorbid health conditions: a systematic review of analytical methods and comparison analysis. International journal of epidemiology **47**(5), 1687–1704 (2018)

[18] Members, W.G., Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B., Flegal, K., Ford, E., Furie, K., Go, A., *et al.*: Heart disease and stroke statistics—2009 update: a report from the american heart association statistics committee and stroke statistics subcommittee. Circulation **119**(3), 21–181 (2009)

[19] Lin, F.R., Thorpe, R., Gordon-Salant, S., Ferrucci, L.: Hearing loss prevalence and risk factors among older adults in the united states. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences **66**(5), 582–590 (2011)

[20] Lee, J.S., DuBois, S.G., Coccia, P.F., Bleyer, A., Olin, R.L., Goldsby, R.E.: Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer **122**(1), 116–123 (2016)

[21] Chao, C., Xu, L., Bhatia, S., Cooper, R., Brar, S., Wong, F.L., Armenian, S.H.: Cardiovascular disease risk profiles in survivors of adolescent and young adult (aya) cancer: the kaiser permanente aya cancer survivors study. Journal of Clinical Oncology **34**(14), 1626–1633 (2016)

[22] Lu, A.T., Quach, A., Wilson, J.G., Reiner, A.P., Aviv, A., Raj, K., Hou, L., Baccarelli, A.A., Li, Y., Stewart, J.D., *et al.*: Dna methylation grimage strongly predicts lifespan and healthspan. Aging (albany NY) **11**(2), 303 (2019)

[23] Warner, B., Ratner, E., Datta, A., Lendasse, A.: A systematic review of phenotypic and epigenetic clocks used for aging and mortality quantification in humans. Aging (Albany NY) **16**(17), 12414 (2024)

[24] Rohmann, N., Geese, T., Nestel, S., Schlicht, K., Geisler, C., Türk, K., Brix, F., Jensen-Kroll, J., Demetrowitsch, T., Bang, C., *et al.*: Metabolic and lifestyle factors accelerate disease onset and alter gut microbiome in inflammatory noncommunicable diseases. BMC medicine **22**(1), 493 (2024)

[25] Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., *et al.*: Uk biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS medicine **12**(3), 1001779 (2015)

[26] Zhang, Y., Wong, G., Mann, G., Muller, S., Yang, J.Y.: Survbenchmark: comprehensive benchmarking study of survival analysis methods using both omics data and clinical data. GigaScience **11**, 071 (2022)

[27] Wiegrebe, S., Kopper, P., Sonabend, R., Bischl, B., Bender, A.: Deep learning for survival analysis: a review. Artificial Intelligence Review **57**(3), 65 (2024)

[28] Aging Consortium, B., Herzog, C.M., Goeminne, L.J., Poganik, J.R., Barzilai, N., Belsky, D.W., Betts-LaCroix, J., Chen, B.H., Chen, M., Cohen, A.A., et al.: Challenges and recommendations for the translation of biomarkers of aging. Nature Aging, 1–12 (2024)

[29] Organization, W.H., et al.: Global status report on non-communicable diseases 2010 (2011)

[30] Torkamani, A., Andersen, K.G., Steinhubl, S.R., Topol, E.J.: High-definition medicine. Cell **170**(5), 828–843 (2017)

[31] Bera, K., Schalper, K.A., Rimm, D.L., Velcheti, V., Madabhushi, A.: Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology. Nature reviews Clinical oncology **16**(11), 703–715 (2019)

[32] Collins, R.: Uk biobank: protocol for a large-scale prospective epidemiological resource (2007)

[33] Littlejohns, T.J., Holliday, J., Gibson, L.M., Garratt, S., Oesingmann, N., Alfaro-Almagro, F., Bell, J.D., Boultwood, C., Collins, R., Conroy, M.C., *et al.*: The uk biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nature communications **11**(1), 2624 (2020)

[34] Liu, Y., Basty, N., Whitcher, B., Bell, J.D., Sorokin, E.P., Bruggen, N., Thomas, E.L., Cule, M.: Genetic architecture of 11 organ traits derived from abdominal mri using deep learning. Elife **10**, 65554 (2021)

[35] Fitzpatrick, J.A., Basty, N., Cule, M., Liu, Y., Bell, J.D., Thomas, E.L., Whitcher, B.: Large-scale analysis of iliopsoas muscle volumes in the uk biobank. Scientific reports **10**(1), 20215 (2020)

[36] Thanaj, M., Basty, N., Whitcher, B., Sorokin, E.P., Liu, Y., Srinivasan, R., Cule, M., Thomas, E.L., Bell, J.D.: Precision mri phenotyping of muscle volume and quality at a population scale. Frontiers in Physiology **15**, 1288657 (2024)

[37] Whitcher, B., Thanaj, M., Cule, M., Liu, Y., Basty, N., Sorokin, E.P., Bell, J.D., Thomas, E.L.: Precision mri phenotyping enables detection of small changes in body composition for longitudinal cohorts. Scientific Reports **12**(1), 3748 (2022)

[38] Ronneberger, O., Fischer, P., Brox, T.: U-net: Convolutional networks for biomedical image segmentation. In: Medical Image Computing and Computer-assisted intervention–MICCAI 2015: 18th International Conference, Munich, Germany, October 5-9, 2015, Proceedings, Part III 18, pp. 234–241 (2015). Springer

[39] Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., Li, J.: Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy **7**(1), 391 (2022)

[40] Koller, D., Schön, G., Schäfer, I., Glaeske, G., Bussche, H., Hansen, H.: Multi-morbidity and long-term care dependency—a five-year follow-up. BMC geriatrics **14**, 1–9 (2014)

[41] Katzman, J.L., Shaham, U., Cloninger, A., Bates, J., Jiang, T., Kluger, Y.: Deepsurv: personalized treatment recommender system using a cox proportional hazards deep neural network. BMC medical research methodology **18**, 1–12 (2018)

[42] Collins, G.S., Moons, K.G., Dhiman, P., Riley, R.D., Beam, A.L., Van Calster, B., Ghassemi, M., Liu, X., Reitsma, J.B., Van Smeden, M., et al.: Tripod+ ai statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. bmj **385** (2024)

[43] Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gøtzsche, P.C., Vandenbroucke, J.P.: The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. The lancet **370**(9596), 1453–1457 (2007)

[44] Selvaraju, R.R., Cogswell, M., Das, A., Vedantam, R., Parikh, D., Batra, D.: Grad-cam: Visual explanations from deep networks via gradient-based localization. In: Proceedings of the IEEE International Conference on Computer Vision, pp. 618–626 (2017)

[45] Hao, J., Kim, Y., Mallavarapu, T., Oh, J.H., Kang, M.: Interpretable deep neural network for cancer survival analysis by integrating genomic and clinical data. BMC medical genomics **12**, 1–13 (2019)

[46] Marengoni, A., Angleman, S., Melis, R., Mangialasche, F., Karp, A., Garmen, A., Meinow, B., Fratiglioni, L.: Aging with multimorbidity: a systematic review

of the literature. Ageing research reviews **10**(4), 430–439 (2011)

[47] Jung, M., Raghu, V.K., Reisert, M., Rieder, H., Rospleszcz, S., Pischon, T., Niendorf, T., Kauczor, H.-U., Völzke, H., Bülow, R., et al.: Deep learning-based body composition analysis from whole-body magnetic resonance imaging to predict all-cause mortality in a large western population. EBioMedicine **110** (2024)

[48] Fry, A., Littlejohns, T.J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., Allen, N.E.: Comparison of sociodemographic and health-related characteristics of uk biobank participants with those of the general population. American journal of epidemiology **186**(9), 1026–1034 (2017)

[49] Freer, C.L., George, E.S., Tan, S.-Y., Abbott, G., Scott, D., Daly, R.M.: Prevalence of sarcopenia and its defining components in non-alcoholic fatty liver disease varies according to the method of assessment and adjustment: Findings from the uk biobank. Calcified Tissue International, 1–11 (2024)

[50] Dickey, A.K., Quick, C., Ducamp, S., Zhu, Z., Feng, Y.-C.A., Naik, H., Balwani, M., Anderson, K.E., Lin, X., Phillips, J.E., *et al.*: Evidence in the uk biobank for the underdiagnosis of erythropoietic protoporphyria. Genetics in Medicine **23**(1), 140–148 (2021)

[51] Spruance, S.L., Reid, J.E., Grace, M., Samore, M.: Hazard ratio in clinical trials. Antimicrobial agents and chemotherapy **48**(8), 2787–2792 (2004)

[52] Chen, H.-C., Kodell, R.L., Cheng, K.F., Chen, J.J.: Assessment of performance of survival prediction models for cancer prognosis. BMC medical research methodology **12**, 1–11 (2012)

Appendix A   Dataset

Dataset details for $n = 60,396$ individuals are provided, including demographics, outcome counts, and biomarker descriptions.

A.1   Demographics

Table A1: Alcohol intake frequency

Sex	Alcohol intake frequency	Percentage (%)	n
Male	Daily or almost daily	22.83	6820
	Never	5.03	1503
	Once or twice a week	25.73	7685
	One to three times a month	9.11	2722
	Prefer not to answer	0.04	12
	Special occasions only	6.44	1925
	Three or four times a week	30.82	9206
	Total	100.00	29873
Female	Daily or almost daily	15.05	4595
	Never	7.22	2204
	Once or twice a week	26.71	8152
	One to three times a month	13.24	4042
	Prefer not to answer	0.02	7
	Special occasions only	13.10	3997
	Three or four times a week	24.66	7526
	Total	100.00	30523

Table A2: Smoking status

Sex	Smoking status	Percentage (%)	n
Male	Current	4.96	1481
	Never	57.70	17236
	Prefer not to answer	0.30	89
	Previous	37.05	11067
	Total	100.00	29873
Female	Current	3.62	1105
	Never	65.07	19860
	Prefer not to answer	0.33	101
	Previous	30.98	9457
	Total	100.00	30523

Table A3: Race

Sex	Race	Percentage (%)	n
Male	Asian or Asian British	1.54	461
	Black or Black British	0.53	159
	Mixed	0.32	95
	Other	0.83	247
	White	96.78	28911
	Total	100.00	29873
Female	Asian or Asian British	1.22	371
	Black or Black British	0.69	211
	Mixed	0.63	193
	Other	0.82	251
	White	96.64	29497
	Total	100.00	30523

Table A4: Education

Sex	Education	Percentage (%)	n
Male	A levels/AS levels or equivalent	11.71	3499
	College or University degree	47.23	14108
	CSEs or equivalent	4.40	1314
	None of the above	6.77	2022
	NVQ or HND or HNC or equivalent	7.98	2383
	O levels/GCSEs or equivalent	17.59	5254
	Other professional qualifications eg: nursing, teaching	3.95	1179
	Prefer not to answer	0.38	114
	Total	100.00	29873
Female	A levels/AS levels or equivalent	14.45	4412
	College or University degree	44.09	13457
	CSEs or equivalent	4.25	1296
	None of the above	6.21	1895
	NVQ or HND or HNC or equivalent	3.28	1001
	O levels/GCSEs or equivalent	21.82	6660
	Other professional qualifications eg: nursing, teaching	5.62	1716
	Prefer not to answer	0.28	86
	Total	100.00	30523

Table A5: Continuous demographic traits

	Male	Female
Mean birth year	1952.47	1953.92
Std birth year	7.65	7.42
Min birth year	1937.00	1937.00
Max birth year	1970.00	1970.00
IQR birth year	13.00	12.00
Mean Townsend deprivation index	-1.95	-1.86

Table A6: Assessment center

Center	Percentage (%)	n
Cheadle (imaging)	38.78	23422
Reading (imaging)	11.42	6895
Newcastle (imaging)	17.83	10766
Bristol (imaging)	1.42	855
Unknown (imaging)	30.56	18458
Total	100.00	60396

A.2 Trait distributions across dataset

Fig. A1: Demographic and basic body traits across dataset splits.

A.3 Data censoring

The UK Biobank dataset used in this study contained participants of middle age and older (50.18 years old was mean age minus two standard deviations) who had medical records collected within a finite time window, therefore data was subject to left and right censoring. Cox PH survival analysis accounted for right censoring via relative risk adjustment; participants whose medical record window were not extended late enough to include future diagnoses were optimised to have higher risk scores than people with diagnoses within the window. Limitation imposed by left censoring was ameliorated by focusing on age-associated diseases which are more prevalent from middle age onwards. Finally, large dataset size assisted the model in learning robust associations inspite of limited window size.

A.4 Disease conditions

Table A7: Non-composite condition definitions by ICD10 code.

Condition group	Condition	ICD10 codes
Metabolic/ endocrine/ nutritional	Diabetes mellitus non-T1	E11, E12, E13, E14
	Hyperuricemia/ gout	E79, M10
	Obesity	E66
	Lipid metabolism disorders	E78
	Thyroid diseases	E01, E02, E03, E04, E05, E06, E07
Genitourinary	Renal insufficiency	N18, N19
	Prostatic hyperplasia	N40
	Gynecological problems	N81, N84, N85, N86, N87, N88, N89, N90, N93, N95
	Urinary incontinence	N39, R32

	Urinary tract calculi	N20
Circulatory	Cardiac insufficiency	I50
	Chronic ischemic heart disease	I20, I25, I21
	Hypertension	I10, I11, I12, I13, I14, I15
	Hypotension	I95
	Cerebral ischemia/ chronic stroke	I60, I61, I62, I63, I64, I69, G45
	Lower limb varicosis	I83, I87
	Cardiac arrhythmias	I44, I45, I46, I47, I48, I49
	Hemorrhoids	I84
	Cardiac valve disorders	I34, I37
	Atherosclerosis/ PAOD	I65, I66, I67, I70, I73
Digestive	Liver disease	K70, K71, K72, K73, K74, K76
	Chronic cholecystitis/ gallstones	K80, K81
	Intestinal diverticulosis	K57
	Chronic gastritis/ GERD	K21, K25, K26, K27, K28, K29
Mental/ behavioural/ mixed	Dementia	F00, F01, F02, F03, F05, G30, G31, R54
	Sexual dysfunction	F52, N48
	Anxiety	F40, F41
	Insomnia	G47, F51
	Depression	F32, F33
	Somatoform disorders	F45
Anemia	Anemia	D50, D51, D52, D53, D55, D56, D57, D58, D59, D60, D61, D63, D64

Nervous system	Parkinson's disease	G20, G21, G22
	Migraine/ chronic headache	G43, G44
	Neuropathies	G50, G51, G52, G53, G54, G55, G56, G57, G58, G59, G60, G61, G62, G63, G64
Respiratory	Bronchitis/ COPD	J40, J41, J42, J43, J44, J47
Musculoskeletal	Osteoporosis	M80, M81, M82
	Joint arthritis	M15, M16, M17, M18, M19
	Rheumatoid arthritis/ chronic polyarthritis	M05, M06, M79
	Chronic low back pain	M40, M41, M42, M43, M44, M45, M47, M48, M50, M51, M52, M53, M54
Allergy/ skin	Psoriasis	L40
	Allergy	H01, J30, L23, L27, L56, K52, K90, T78, T88
Eye	Severe vision reduction	H17, H18, H25, H26, H27, H28, H31, H33, H34, H35, H36, H40, H43, H47, H54
Ear	Dizziness	H81, H82, R42
	Severe hearing loss	H90, H91

Cancer	Cancer	C00, C01, C02, C03, C04, C05, C06, C07, C08, C09, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C43, C44, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C82, C83,C84, C85, C86, C87, C88, C89, C90, C91, C92, C93, C94, C95, C96, C97, D00, D01, D02, D03, D04, D05, D06, D07, D08, D09, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48

Table A8: Condition event counts.

Condition	Male	Female
All cause morbidity	26335	27318
All cause mortality	277	146
Allergy	5835	6380
Anemia	1559	3020
Anxiety	1571	2728
Atherosclerosis/PAOD	796	807
Bronchitis/COPD	1571	1441

Cancer	3865	3570
Cardiac arrhythmias	3122	1758
Cardiac insufficiency	508	185
Cardiac valve disorders	317	219
Cerebral ischemia/chronic stroke	1130	676
Chronic cholecystitis/gallstones	1185	2177
Chronic gastritis/GERD	6472	6220
Chronic ischemic heart disease	3220	1253
Chronic low back pain	6352	6903
Dementia	169	107
Depression	2497	4194
Diabetes mellitus non-T1	2215	1158
Dizziness	475	791
Gynecological problems	4	10193
Hemorrhoids	1925	1672
Hypertension	11184	7618
Hyperuricemia/gout	1725	173
Hypotension	554	467
Insomnia	1135	775
Intestinal diverticulosis	3676	3367
Joint arthritis	5267	6513
Lipid metabolism disorders	8400	4681
Liver disease	642	556
Lower limb varicosis	1124	1756
Migraine/chronic headache	1422	3249
Neuropathies	2217	2954
Obesity	1956	1823
Osteoporosis	318	1825

Parkinson's disease	96	46
Prostatic hyperplasia	4425	2
Psoriasis	1015	908
Renal insufficiency	997	815
Rheumatoid arthritis/chronic polyarthritis	4145	5153
Severe hearing loss	1294	865
Severe vision reduction	5048	5203
Sexual dysfunction	1063	105
Somatoform disorders	123	207
Thyroid diseases	1058	3907
Urinary incontinence	1529	3475
Urinary tract calculi	1016	418

A.5 Quartile definitions

Table A9: OnsetNet score quartile boundaries computed for the best model (demog+bb+bbc+sbc+blood) from the train-val dataset.

Condition	Male			Female		
	Q1 end	Q2 end	Q3 end	Q1 end	Q2 end	Q3 end
All cause morbidity	0.403	0.629	0.869	0.531	0.761	1.016
All cause mortality	-0.289	1.610	3.678	-0.772	0.963	2.914
Allergy	0.471	0.693	0.943	0.502	0.678	0.888
Anemia	-1.593	-1.263	-0.895	-1.077	-0.527	0.102
Anxiety	-0.037	0.415	0.905	0.582	1.009	1.523
Atherosclerosis/PAOD	0.139	0.511	0.903	0.121	0.533	0.958
Bronchitis/COPD	0.390	0.750	1.136	0.402	0.721	1.048
Cancer	-0.881	-0.788	-0.684	-1.011	-0.762	-0.373

Cardiac arrhythmias	-0.156	0.134	0.442	-0.674	-0.390	-0.065
Cardiac insufficiency	0.337	0.918	1.529	-0.601	-0.043	0.580
Cardiac valve disorders	-1.962	-1.542	-1.102	-2.396	-1.856	-1.254
Cerebral ischemia/chronic stroke	1.351	1.683	2.056	0.788	1.079	1.420
Chronic cholecystitis/gall-stones	-1.013	-0.588	-0.183	-0.539	-0.069	0.505
Chronic gastritis/GERD	0.110	0.414	0.734	-0.009	0.291	0.630
Chronic ischemic heart disease	0.446	0.885	1.399	-0.674	-0.242	0.281
Chronic low back pain	-0.204	0.018	0.244	-0.122	0.100	0.332
Dementia	-1.546	-0.749	0.086	-1.812	-1.049	-0.223
Depression	-1.068	-0.657	-0.220	-0.473	-0.098	0.321
Diabetes mellitus non-T1	-1.534	-0.389	1.001	-2.371	-1.346	-0.071
Dizziness	-1.028	-0.817	-0.611	-0.438	-0.198	0.047
Gynecological problems	-2.602	-2.414	-2.192	2.871	3.068	3.244
Hemorrhoids	-0.109	0.071	0.287	-0.405	-0.199	0.049
Hypertension	2.360	2.897	3.462	1.762	2.289	2.892
Hyperuricemia/gout	1.538	2.436	3.370	-1.022	-0.314	0.569
Hypotension	-2.655	-2.119	-1.492	-3.003	-2.327	-1.525
Insomnia	0.593	1.034	1.574	0.349	0.654	1.042
Intestinal diverticulosis	-0.645	-0.328	0.035	-0.769	-0.478	-0.138
Joint arthritis	-0.260	0.026	0.338	-0.043	0.272	0.622
Lipid metabolism disorders	1.175	1.696	2.277	0.407	0.931	1.495
Liver disease	-2.166	-1.368	-0.404	-2.284	-1.524	-0.610
Lower limb varicosis	-0.014	0.257	0.519	0.562	0.820	1.080
Migraine/chronic headache	-0.332	-0.071	0.201	0.468	0.774	1.075
Neuropathies	0.229	0.518	0.848	0.485	0.773	1.102

Obesity	-0.204	0.776	1.834	-0.821	0.193	1.460
Osteoporosis	-1.091	-0.697	-0.260	0.695	1.149	1.619
Parkinson's disease	1.555	2.370	3.106	0.437	1.174	1.921
Prostatic hyperplasia	3.460	3.740	4.024	-1.954	-1.698	-1.408
Psoriasis	1.084	1.387	1.668	0.769	1.079	1.401
Renal insufficiency	-2.061	-1.331	-0.523	-1.946	-1.279	-0.528
Rheumatoid arthritis/chronic polyarthritis	-0.549	-0.311	-0.061	-0.359	-0.098	0.196
Severe hearing loss	-0.498	-0.349	-0.192	-0.934	-0.781	-0.610
Severe vision reduction	1.281	1.457	1.609	1.390	1.551	1.715
Sexual dysfunction	1.134	1.380	1.652	-1.461	-1.139	-0.658
Somatoform disorders	0.152	0.518	0.839	0.486	0.931	1.340
Thyroid diseases	-0.640	-0.421	-0.162	0.708	0.931	1.191
Urinary incontinence	-0.404	-0.240	-0.054	0.419	0.677	0.980
Urinary tract calculi	-0.231	0.077	0.410	-1.140	-0.861	-0.542

A.6 Data pre-processing

The UK Biobank study protocol is publically available [25]. The inclusion flowchart is given in A2.

Fig. A2: Pre-processing flowchart for data utilized in the study.

Body composition variables

The sbc variable with dimension $[5 \times 370]$ consisted of mass, subcutaneous adipose tissue, muscle, visceral adipose tissue, thigh intramuscular and intermuscular adipose tissue channels measured along 370 vertical slices, segmented and landmarked (at mid-thigh, hip, T12 vertebra as top of the iliopsoas muscle, and shoulder) with a previously published deep learning system [34–37]. Spatial body composition was computed from tissue segmentation maps by summing tissue volume for each vertical slice to yield a $[1 \times 370]$ vector per tissue type along the height dimension, followed by linear interpolation to register vectors to sex-specific average landmark positions and concatenation to combine vectors into a matrix with dimension $[5 \times 370]$.

Appendix B   Architecture

OnsetNet's architecture is illustrated in Figure .

Fig. B3: Architecture for neural network OnsetNet with channel sizes and PyTorch naming convention. Input variables shown in green. m_g denotes input dimensions of trait group g. Encoders produce feature vectors of fixed length $k \in \{128, 256, 512\}$, where k is a hyperparameter.

Appendix C Additional Results

C.1 Addition of biomarker inputs

Table C10: Difference in internal test C-index from adding additional input types to change from input type 1 to input type 2. C-index values denote average over 47 conditions and 5 folds. * (**) denotes significance at $p = 0.05$ (Bonferroni corrected $p = 2.27E - 3$) level.

Input type 1		Input type 2		Difference	P-value
Name	C-index	Name	C-index		
demog	5.863E-1	demog+bb	6.404E-1	5.415E-2	9.676E-15 **
demog	5.863E-1	demog+bb+bbc	6.649E-1	7.859E-2	4.274E-27 **
demog	5.863E-1	demog+bb+sbc	6.699E-1	8.362E-2	8.809E-30 **
demog	5.863E-1	demog+bb+blood	6.677E-1	8.137E-2	4.182E-25 **
demog	5.863E-1	demog+bb+bbc blood	6.799E-1	9.362E-2	2.851E-31 **
demog	5.863E-1	demog+bb+sbc blood	6.82E-1	9.567E-2	1.523E-32 **
demog	5.863E-1	demog+bb+bbc sbc+blood	6.83E-1	9.668E-2	3.973E-33 **
demog+bb	6.404E-1	demog+bb+bbc	6.649E-1	2.444E-2	6.848E-4 **
demog+bb	6.404E-1	demog+bb+sbc	6.699E-1	2.947E-2	4.805E-5 **
demog+bb	6.404E-1	demog+bb+blood	6.677E-1	2.722E-2	4.478E-4 **
demog+bb	6.404E-1	demog+bb+bbc blood	6.799E-1	3.947E-2	5.225E-7 **
demog+bb	6.404E-1	demog+bb+sbc blood	6.82E-1	4.152E-2	1.265E-7 **
demog+bb	6.404E-1	demog+bb+bbc sbc+blood	6.83E-1	4.253E-2	6.294E-8 **

demog+bb+bbc	6.649E-1	demog+bb+bbc blood	6.799E-1	1.503E-2	5.523E-2
demog+bb+bbc	6.649E-1	demog+bb+bbc sbc+blood	6.83E-1	1.809E-2	2.078E-2 *
demog+bb+sbc	6.699E-1	demog+bb+sbc blood	6.82E-1	1.205E-2	1.246E-1
demog+bb+sbc	6.699E-1	demog+bb+bbc sbc+blood	6.83E-1	1.306E-2	9.595E-2
demog+bb+blood	6.677E-1	demog+bb+bbc blood	6.799E-1	1.224E-2	1.42E-1
demog+bb+blood	6.677E-1	demog+bb+sbc blood	6.82E-1	1.43E-2	8.59E-2
demog+bb+blood	6.677E-1	demog+bb+bbc sbc+blood	6.83E-1	1.531E-2	6.594E-2
demog+bb+bbc blood	6.799E-1	demog+bb+bbc sbc+blood	6.83E-1	3.062E-3	7.142E-1
demog+bb+sbc blood	6.82E-1	demog+bb+bbc sbc+blood	6.83E-1	1.01E-3	9.037E-1

C.2 Test performance

Fig. C4: External test set C-index across disease conditions for neural network and linear architectures. Gray error bars illustrate 95% confidence intervals.

Fig. C5: Internal test set C-index across disease conditions for neural network architectures. Gray error bars illustrate 95% confidence intervals.

Fig. C6: External test set C-index across disease conditions for neural network architectures. Gray error bars illustrate 95% confidence intervals.

C.3   Kaplan-Meier curves

Fig. C7: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (1/9)

Fig. C8: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (2/9)

Fig. C9: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (3/9)

Fig. C10: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (4/9)

Fig. C11: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (5/9)

Fig. C12: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (6/9)

Fig. C13: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (7/9)

Fig. C14: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (8/9)

OnsetNet Q1

	0	20	40	60	80
At risk	15059	15054	15002	14259	1307
Censored	0	0	0	649	13525
Events	0	5	57	151	227

OnsetNet Q2

	0	20	40	60	80
At risk	15115	15108	15048	13314	766
Censored	0	0	0	1578	14017
Events	0	7	67	223	332

OnsetNet Q3

	0	20	40	60	80
At risk	15127	15117	15045	12193	462
Censored	0	0	0	2689	14314
Events	1	11	83	246	352

OnsetNet Q4

	0	20	40	60	80
At risk	15094	15076	14968	8957	134
Censored	0	0	0	5705	14437
Events	0	18	126	432	523

Fig. C15: Kaplan-Meier curves plotting survival probability (vertical) against age in years (horizontal). (9/9)

C.4   Inter-disease risk analysis

C.4.1   Onset acceleration correlation

The clustering dendrogram in Figure 5 utilized UPGMA (unweighted pair group method with arithmetic mean) hierarchical agglomerative clustering for the linkage function (SciPy *cluster.hierarchy.linkage*) with cosine distance between correlation vectors as the clustering metric, where $d(u,v) = \sum_{i,j} \frac{c(u[i],v[j])}{(|u||v|)}$ defined the linkage function between non-identical clusters u and v, i (j) indexes members of cluster u (v), and c denotes cosine distance. Color red (blue) indicates positive (negative)

Fig. C16: All inter-disease Pearson correlations r for non-statin users. Color red (blue) indicates positive (negative) correlation and color intensity scales with correlation magnitude. Conditions with internal test C-index < 0.6 and correlations with $p > 3.46E - 5$ (Bonferroni corrected) indicated in gray.

Fig. C17: All inter-disease Pearson correlations r, statin users included. Color red (blue) indicates positive (negative) correlation and color intensity scales with correlation magnitude. Conditions with internal test C-index < 0.6 and correlations with $p > 3.46E-5$ (Bonferroni corrected) indicated in gray.

Fig. C18: All-to-all OnsetNet score quartile correlation for conditions with internal test C-index ≥ 0.6, clustered by cosine distance between correlation vectors. Color red (blue) indicates positive (negative) correlation and color intensity scales with correlation magnitude. Statin users were included and 28 out of 1444 entries with $p > 3.46E - 5$ (Bonferroni corrected) were set to 0 for cosine distance computation.

Fig. C19: All inter-disease Pearson correlations r for non-statin users without Bonferroni correction. Color red (blue) indicates positive (negative) correlation and color intensity scales with correlation magnitude. Conditions with internal test C-index < 0.6 and correlations with $p > 0.05$ indicated in gray.

Fig. C20: All-to-all OnsetNet score quartile correlation for non-statin users and conditions with internal test C-index ≥ 0.6, clustered by cosine distance between correlation vectors. Color red (blue) indicates positive (negative) correlation and color intensity scales with correlation magnitude. 12 out of 1444 entries with $p > 0.05$ (no Bonferroni correction) were set to 0 for cosine distance computation.

C.4.2 Associations in onset acceleration correlation

Table C11: Top 5 conditions with highest onset acceleration risk quartile correlation across non-statin users for conditions with internal test C-index ≥ 0.6. All correlations in the top 5 were statistically significant ($p \leq 9.41E - 77 \pm 1.29E - 75$).

Condition	Top 5 conditions by onset acceleration risk correlation
All cause morbidity	Depression (0.83), anxiety (0.82), dementia (0.82), insomnia (0.81), rheumatoid arthritis/chronic polyarthritis (0.79)
All cause mortality	Anxiety (0.86), dementia (0.84), depression (0.80), all cause morbidity (0.78), migraine/chronic headache (0.77)
Diabetes mellitus non-T1	Chronic ischemic heart disease (0.64), lipid metabolism disorders (0.63), insomnia (0.62), intestinal diverticulosis (0.60), urinary tract calculi (0.56)
Hyperuricemia/ gout	Hypertension (0.70), lipid metabolism disorders (0.61), joint arthritis (0.50), chronic ischemic heart disease (0.50), cerebral ischemia/chronic stroke (0.49)
Lipid metabolism disorders	Chronic ischemic heart disease (0.79), hypertension (0.79), cerebral ischemia/chronic stroke (0.70), diabetes mellitus non-T1 (0.63), hyperuricemia/gout (0.61)
Obesity	Insomnia (0.78), neuropathies (0.78), rheumatoid arthritis/chronic polyarthritis (0.76), intestinal diverticulosis (0.75), liver disease (0.67)
Thyroid diseases	Chronic ischemic heart disease (0.73), cardiac insufficiency (0.68), insomnia (0.67), neuropathies (0.66), rheumatoid arthritis/chronic polyarthritis (0.62)
Chronic cholecystitis/ gallstones	Intestinal diverticulosis (0.76), chronic gastritis/GERD (0.71), liver disease (0.71), chronic ischemic heart disease (0.70), insomnia (0.67)
Chronic gastritis/ GERD	Intestinal diverticulosis (0.85), rheumatoid arthritis/chronic polyarthritis (0.79), all cause morbidity (0.78), urinary tract calculi (0.77), insomnia (0.77)

Intestinal diverticulosis	Chronic gastritis/GERD (0.85), liver disease (0.84), rheumatoid arthritis/chronic polyarthritis (0.82), insomnia (0.81), urinary tract calculi (0.79)
Liver disease	Intestinal diverticulosis (0.84), rheumatoid arthritis/chronic polyarthritis (0.78), insomnia (0.76), chronic gastritis/GERD (0.73), all cause morbidity (0.72)
Gynecological problems	Anxiety (0.61), depression (0.60), all cause morbidity (0.56), all cause mortality (0.55), anemia (0.55)
Prostatic hyperplasia	Cerebral ischemia/chronic stroke (0.42), chronic ischemic heart disease (0.40), lipid metabolism disorders (0.33), urinary incontinence (0.33), chronic cholecystitis/gallstones (0.31)
Renal insufficiency	Thyroid diseases (0.51), cardiac insufficiency (0.47), hyperuricemia/gout (0.42), chronic ischemic heart disease (0.42), hypotension (0.41)
Urinary incontinence	Rheumatoid arthritis/chronic polyarthritis (0.73), sexual dysfunction (0.71), depression (0.69), insomnia (0.68), all cause morbidity (0.68)
Urinary tract calculi	Intestinal diverticulosis (0.79), chronic gastritis/GERD (0.77), liver disease (0.68), chronic cholecystitis/gallstones (0.65), insomnia (0.65)
Atherosclerosis/ PAOD	Cardiac valve disorders (0.78), anemia (0.72), cardiac arrhythmias (0.70), cardiac insufficiency (0.69), dementia (0.68)
Cardiac arrhythmias	Cardiac insufficiency (0.80), cardiac valve disorders (0.76), dementia (0.70), atherosclerosis/PAOD (0.70), hypotension (0.67)
Cardiac insufficiency	Cardiac arrhythmias (0.80), dementia (0.75), hypotension (0.73), rheumatoid arthritis/chronic polyarthritis (0.71), cardiac valve disorders (0.71)
Cardiac valve disorders	Hypotension (0.79), atherosclerosis/PAOD (0.78), dementia (0.78), anemia (0.78), cardiac arrhythmias (0.76)

Cerebral ischemia/ chronic stroke	Chronic ischemic heart disease (0.73), lipid metabolism disorders (0.70), bronchitis/COPD (0.65), hypertension (0.65), thyroid diseases (0.58)
Chronic ischemic heart disease	Lipid metabolism disorders (0.79), thyroid diseases (0.73), cerebral ischemia/chronic stroke (0.73), chronic cholecystitis/gallstones (0.70), diabetes mellitus non-T1 (0.64)
Hypertension	Lipid metabolism disorders (0.79), hyperuricemia/gout (0.70), cerebral ischemia/chronic stroke (0.65), chronic ischemic heart disease (0.63), chronic cholecystitis/gallstones (0.55)
Hypotension	Anemia (0.84), cardiac valve disorders (0.79), anxiety (0.76), depression (0.73), sexual dysfunction (0.73)
Lower limb varicosis	Cardiac arrhythmias (0.52), parkinson's disease (0.41), atherosclerosis/PAOD (0.37), bronchitis/COPD (0.36), thyroid diseases (0.35)
Migraine/ chronic headache	Anxiety (0.78), depression (0.77), all cause mortality (0.77), dementia (0.75), all cause morbidity (0.69)
Neuropathies	Rheumatoid arthritis/chronic polyarthritis (0.84), insomnia (0.79), obesity (0.78), chronic gastritis/GERD (0.71), intestinal diverticulosis (0.71)
Parkinson's disease	Dementia (0.73), all cause mortality (0.72), cardiac arrhythmias (0.64), cardiac insufficiency (0.64), migraine/chronic headache (0.63)
Joint arthritis	Neuropathies (0.63), cerebral ischemia/chronic stroke (0.58), hypertension (0.54), obesity (0.54), chronic ischemic heart disease (0.53)
Osteoporosis	Bronchitis/COPD (0.47), cerebral ischemia/chronic stroke (0.23), atherosclerosis/PAOD (0.19), lower limb varicosis (0.16), chronic ischemic heart disease (0.08)
Rheumatoid arthritis/ chronic polyarthritis	Neuropathies (0.84), insomnia (0.83), intestinal diverticulosis (0.82), chronic gastritis/GERD (0.79), depression (0.79)

Anxiety	Depression (0.90), all cause mortality (0.86), all cause morbidity (0.82), dementia (0.81), migraine/chronic headache (0.78)
Dementia	All cause mortality (0.84), all cause morbidity (0.82), depression (0.81), anxiety (0.81), cardiac valve disorders (0.78)
Depression	Anxiety (0.90), all cause morbidity (0.83), dementia (0.81), all cause mortality (0.80), rheumatoid arthritis/chronic polyarthritis (0.79)
Insomnia	Rheumatoid arthritis/chronic polyarthritis (0.83), intestinal diverticulosis (0.81), all cause morbidity (0.81), neuropathies (0.79), depression (0.79)
Sexual dysfunction	Anxiety (0.74), all cause mortality (0.73), anemia (0.73), hypotension (0.73), depression (0.71)
Anemia	Hypotension (0.84), cardiac valve disorders (0.78), anxiety (0.74), sexual dysfunction (0.73), atherosclerosis/PAOD (0.72)
Bronchitis/ COPD	Cerebral ischemia/chronic stroke (0.65), cardiac insufficiency (0.60), chronic gastritis/GERD (0.57), dementia (0.54), atherosclerosis/PAOD (0.54)

C.4.3 Prognostic survival analysis

Prognostic risk evaluation

Although commonly used exclusively for prognostic prediction in biomedical contexts [27], Cox PH models do not assume events must occur after trait measurement baseline. The Cox PH objective function specifies a well-defined optimization problem for risk prediction functions regardless of whether variable x_i (Section 2.3) contains traits of the individual measured before or after the event occurred. Model h_θ^d was trained and evaluated as a general (not exclusively prognostic) risk prediction model taking variable x_i containing imperfect information for event time of condition d whether retrospective or prospective. Prognostic value of the model was separately verified in Section 3.3 with exclusion of events that occurred before trait measurement time.

Fig. C21: All-to-all adjusted log hazard ratios for OnsetNet risk Q4 (Q1 as reference) given primary adjustment with demographic variables. Color red (blue) indicates positive (negative) log hazard ratios and color intensity scales with log hazard ratio magnitude. Results with adjusted hazard ratio $p > 0.05$ (without Bonferroni correction) or Schoenfeld residual $p \leq 0.05$ omitted in gray. Entries that remained statistically significant after secondary adjustment with basic body traits are underlined to denote robustness to change in adjustment.

Fig. C22: All-to-all log adjusted hazard ratios for binarized OnsetNet risk (above-median; below-median as reference) given primary adjustment with demographic variables. Color red (blue) indicates positive (negative) log hazard ratios and color intensity scales with log hazard ratio magnitude. Results with adjusted hazard ratio $p > 0.05$ (without Bonferroni correction) or Schoenfeld residual $p \leq 0.05$ omitted in gray. Entries that remained statistically significant after secondary adjustment with basic body traits are underlined to denote robustness to change in adjustment.

Fig. C23: All-to-all log adjusted hazard ratios for binarized OnsetNet risk (above-median; below-median as reference) given primary adjustment with demographic variables. Color red (blue) indicates positive (negative) log hazard ratios and color intensity scales with log hazard ratio magnitude. Statistically insignificant adjusted hazard ratios with $p > 9.05E - 7$ (Bonferroni corrected $p > 0.05$) or Schoenfeld residual $p \leq 0.05$ are omitted in gray. Entries that remained statistically significant after secondary adjustment with basic body traits are underlined to denote robustness to change in adjustment.

C.5 Biomarker saliency

Saliency maps for full traits (demog+bb+bbc+sbc+blood) and full univariate traits (demog+bb+bbc+blood) OnsetNet models are provided.

C.5.1 Full traits model

Fig. C24: Univariate saliency for full traits model (female). Top 10 traits for each row are labelled.

Fig. C25: Univariate saliency for full traits model (male). Top 10 traits for each row are labelled.

Fig. C26: Spatial body composition saliency across conditions (male MASS).

Fig. C27: Spatial body composition saliency across conditions (male MUSC).

Fig. C28: Spatial body composition saliency across conditions (male SAT).

Fig. C29: Spatial body composition saliency across conditions (male VAT).

Fig. C30: Spatial body composition saliency across conditions (male TMAT).

Fig. C31: Spatial body composition saliency across conditions (female MASS).

Fig. C32: Spatial body composition saliency across conditions (female MUSC).

Fig. C33: Spatial body composition saliency across conditions (female SAT).

Fig. C34: Spatial body composition saliency across conditions (female VAT).

Fig. C35: Spatial body composition saliency across conditions (female TMAT).

C.5.2 Full univariate traits model

Fig. C36: Univariate saliency for full univariate traits model (female). Top 10 traits for each row are labelled.

Fig. C37: Univariate saliency for full univariate traits model (male). Top 10 traits for each row are labelled.

Appendix D   Reporting checklists

TRIPOD+AI for Abstracts

Section and item	Checklist item
Title	
1 x	Identify the study as developing or evaluating the performance of a multivariable prediction model, the target population, and the outcome to be predicted
Background	
2 x	Provide a brief explanation of the healthcare context and rationale for developing or evaluating the performance of all models
Objectives	
3 x	Specify the study objectives, including whether the study describes model development, evaluation, or both
Methods	
4 x	Describe the sources of data
5 x	Describe the eligibility criteria and setting where the data were collected
6 x	Specify the outcome to be predicted by the model, including time horizon of predictions in case of prognostic models
7 x	Specify the type of model, a summary of the model-building steps, and the method for internal validation†
8 x	Specify the measures used to assess model performance (eg, discrimination, calibration, clinical utility)
Results	
9 x	Report the number of participants and outcome events
10 x	Summarise the predictors in the final model†
11 x	Report model performance estimates (with confidence intervals)
Discussion	
12 x	Give an overall interpretation of the main results
Registration	
13 N/A	Give the registration number and name of the registry or repository

Section/Topic	Item	Development / evaluation[1]	Checklist item	Reported on page
TITLE				
Title	1	D;E	Identify the study as developing or evaluating the performance of a multivariable prediction model, the target population, and the outcome to be predicted	1
ABSTRACT				
Abstract	2	D;E	See TRIPOD+AI for Abstracts checklist	App D
INTRODUCTION				
Background	3a	D;E	Explain the healthcare context (including whether diagnostic or prognostic) and rationale for developing or evaluating the prediction model, including references to existing models	2, 3
	3b	D;E	Describe the target population and the intended purpose of the prediction model in the context of the care pathway, including its intended users (e.g., healthcare professionals, patients, public)	5
	3c	D;E	Describe any known health inequalities between sociodemographic groups	2, 23
Objectives	4	D;E	Specify the study objectives, including whether the study describes the development or validation of a prediction model (or both)	3
METHODS				
Data	5a	D;E	Describe the sources of data separately for the development and evaluation datasets (e.g., randomised trial, cohort, routine care or registry data), the rationale for using these data, and representativeness of the data	5
	5b	D;E	Specify the dates of the collected participant data, including start and end of participant accrual; and, if applicable, end of follow-up	5
Participants	6a	D;E	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including the number and location of centres	5
	6b	D;E	Describe the eligibility criteria for study participants	5, App A
	6c	D;E	Give details of any treatments received, and how they were handled during model development or evaluation, if relevant	N/A
Data preparation	7	D;E	Describe any data pre-processing and quality checking, including whether this was similar across relevant sociodemographic groups	7, App A
Outcome	8a	D;E	Clearly define the outcome that is being predicted and the time horizon, including how and when assessed, the rationale for choosing this outcome, and whether the method of outcome assessment is consistent across sociodemographic groups	7, 8
	8b	D;E	If outcome assessment requires subjective interpretation, describe the qualifications and demographic characteristics of the outcome assessors	N/A
	8c	D;E	Report any actions to blind assessment of the outcome to be predicted	N/A
Predictors	9a	D	Describe the choice of initial predictors (e.g., literature, previous models, all available predictors) and any pre-selection of predictors before model building	5
	9b	D;E	Clearly define all predictors, including how and when they were measured (and any actions to blind assessment of predictors for the outcome and other predictors)	5, 6, App A
	9c	D;E	If predictor measurement requires subjective interpretation, describe the qualifications and demographic characteristics of the predictor assessors	N/A
Sample size	10	D;E	Explain how the study size was arrived at (separately for development and evaluation), and justify that the study size was sufficient to answer the research question. Include details of any sample size calculation	5, App A
Missing data	11	D;E	Describe how missing data were handled. Provide reasons for omitting any data	5, App A
Analytical methods	12a	D	Describe how the data were used (e.g., for development and evaluation of model performance) in the analysis, including whether the data were partitioned, considering any sample size requirements	5, App A
	12b	D	Depending on the type of model, describe how predictors were handled in the analyses (functional form, rescaling, transformation, or any standardisation).	7, App A
	12c	D	Specify the type of model, rationale[2], all model-building steps, including any hyperparameter tuning, and method for internal validation	7, 8
	12d	D;E	Describe if and how any heterogeneity in estimates of model parameter values and model performance was handled and quantified across clusters (e.g., hospitals, countries). See TRIPOD-Cluster for additional considerations[3]	N/A
	12e	D;E	Specify all measures and plots used (and their rationale) to evaluate model performance (e.g., discrimination, calibration, clinical utility) and, if relevant, to compare multiple models	8
	12f	E	Describe any model updating (e.g., recalibration) arising from the model evaluation, either overall or for particular sociodemographic groups or settings	N/A
	12g	E	For model evaluation, describe how the model predictions were calculated (e.g., formula, code, object, application programming interface)	8
Class imbalance	13	D;E	If class imbalance methods were used, state why and how this was done, and any subsequent methods to recalibrate the model or the model predictions	N/A
Fairness	14	D;E	Describe any approaches that were used to address model fairness and their rationale	9, 23
Model output	15	D	Specify the output of the prediction model (e.g., probabilities, classification). Provide details and rationale for any classification and how the thresholds were identified	8, App A

---

[1] D=items relevant only to the development of a prediction model; E=items relating solely to the evaluation of a prediction model; D;E=items applicable to both the development and evaluation of a prediction model

[2] Separately for all model building approaches.

[3] TRIPOD-Cluster is a checklist of reporting recommendations for studies developing or validating models that explicitly account for clustering or explore heterogeneity in model performance (eg, at different hospitals or centres). Debray et al, BMJ 2023; 380: e071018 [DOI: 10.1136/bmj-2022-071018]

Training versus evaluation	16	D;E	Identify any differences between the development and evaluation data in healthcare setting, eligibility criteria, outcome, and predictors	11, 36
Ethical approval	17	D;E	Name the institutional research board or ethics committee that approved the study and describe the participant-informed consent or the ethics committee waiver of informed consent	25
OPEN SCIENCE				
Funding	18a	D;E	Give the source of funding and the role of the funders for the present study	24
Conflicts of interest	18b	D;E	Declare any conflicts of interest and financial disclosures for all authors	24
Protocol	18c	D;E	Indicate where the study protocol can be accessed or state that a protocol was not prepared	5, 25
Registration	18d	D;E	Provide registration information for the study, including register name and registration number, or state that the study was not registered	5, 25
Data sharing	18e	D;E	Provide details of the availability of the study data	25
Code sharing	18f	D;E	Provide details of the availability of the analytical code[4]	8
PATIENT & PUBLIC INVOLVEMENT				
Patient & Public Involvement	19	D;E	Provide details of any patient and public involvement during the design, conduct, reporting, interpretation, or dissemination of the study or state no involvement.	25
RESULTS				
Participants	20a	D;E	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	App A
	20b	D;E	Report the characteristics overall and, where applicable, for each data source or setting, including the key dates, key predictors (including demographics), treatments received, sample size, number of outcome events, follow-up time, and amount of missing data. A table may be helpful. Report any differences across key demographic groups.	11, App A
	20c	E	For model evaluation, show a comparison with the development data of the distribution of important predictors (demographics, predictors, and outcome).	11, App A
Model development	21	D;E	Specify the number of participants and outcome events in each analysis (e.g., for model development, hyperparameter tuning, model evaluation)	11, App A, C
Model specification	22	D	Provide details of the full prediction model (e.g., formula, code, object, application programming interface) to allow predictions in new individuals and to enable third-party evaluation and implementation, including any restrictions to access or re-use (e.g., freely available, proprietary)[5]	8
Model performance	23a	D;E	Report model performance estimates with confidence intervals, including for any key subgroups (e.g., sociodemographic). Consider plots to aid presentation.	13, App C
	23b	D;E	If examined, report results of any heterogeneity in model performance across clusters. See TRIPOD Cluster for additional details[3].	N/A
Model updating	24	E	Report the results from any model updating, including the updated model and subsequent performance	N/A
DISCUSSION				
Interpretation	25	D;E	Give an overall interpretation of the main results, including issues of fairness in the context of the objectives and previous studies	23
Limitations	26	D;E	Discuss any limitations of the study (such as a non-representative sample, sample size, overfitting, missing data) and their effects on any biases, statistical uncertainty, and generalizability	23
Usability of the model in the context of current care	27a	D	Describe how poor quality or unavailable input data (e.g., predictor values) should be assessed and handled when implementing the prediction model	App A
	27b	D	Specify whether users will be required to interact in the handling of the input data or use of the model, and what level of expertise is required of users	N/A
	27c	D;E	Discuss any next steps for future research, with a specific view to applicability and generalizability of the model	4, 5, 23, 24

From: Collins GS, Moons KGM, Dhiman P, et al. *BMJ* 2024;385:e078378. doi:10.1136/bmj-2023-078378

---

[4] This relates to the analysis code, for example, any data cleaning, feature engineering, model building, evaluation.
[5] This relates to the code to implement the model to get estimates of risk for a new individual.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	X
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	X
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	X
Objectives	3	State specific objectives, including any prespecified hypotheses	X
Methods			
Study design	4	Present key elements of study design early in the paper	X
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	X
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants	X
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	X
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	X
Bias	9	Describe any efforts to address potential sources of bias	X
Study size	10	Explain how the study size was arrived at	X
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	X
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	X
		(*b*) Describe any methods used to examine subgroups and interactions	X
		(*c*) Explain how missing data were addressed	X
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy	N/A
		(*e*) Describe any sensitivity analyses	X

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	X
		(b) Give reasons for non-participation at each stage	X
		(c) Consider use of a flow diagram	X
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	X
		(b) Indicate number of participants with missing data for each variable of interest	X
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	X
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	X
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or summary measures	
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	X
		(*b*) Report category boundaries when continuous variables were categorized	X
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	X

Discussion

Key results	18	Summarise key results with reference to study objectives	X
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	X
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	X
Generalisability	21	Discuss the generalisability (external validity) of the study results	X

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	X

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.